Q-omics provides the consensus-scored PHOX2B profile across patient tissues and cancer cell-line models. PHOX2B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHOX2B is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, PHOX2B protein abundance shows 18,701 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, COAD, and PDAC as cancer lineages where PHOX2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHOX2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHOX2B survival associations across molecular data types. PHOX2B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHOX2B RNA expression–survival associations across cancer types. High PHOX2B expression shows unfavorable associations in KIRC, OV, THYM, LUSC, UCEC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHOX2B RNA expression.
This table summarizes PHOX2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PHOX2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHOX2B shows lower tumor expression in COAD, READ, STAD and KIRC and higher tumor expression in LUAD and UCEC. The COAD box plot shows higher PHOX2B RNA expression in normal versus tumor tissue (log2 FC = −1.457, t-test p < 0.001).
This table shows molecular features associated with PHOX2B in patient tissues and cancer cell lines. In patient samples, PHOX2B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHOX2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
